Effects of Melatonin and Vitamin E on Peripheral Neuropathic Pain in Streptozotocin-Induced Diabetic Rats by Reza Heidari et al.
Iranian Journal of Basic Medical Sciences 
Vol. 13, No. 2, Spring 2010, 1-8 
Received: Oct 21, 2009; Accepted: Feb 4, 2010 
 
 Iran J Basic Med Sci, Vol. 13, No. 2, Spring 2010     1
 
Original article  
 
 
Effects of Melatonin and Vitamin E on Peripheral Neuropathic Pain in 
Streptozotocin-Induced Diabetic Rats 
 
*
1Farrin Babaei-Balderlou, 
1Samad Zare, 
1Reza Heidari, 
1Farah Farrokhi 
 
Abstract 
 
Objective(s) 
Previous studies have indicated that diabetes mellitus might be accompanied by neuropathic pain. Oxidative 
stress is implicated as a final common pathway in development of diabetic neuropathy. Pharmacological 
interventions targeted at inhibiting free radical production have shown beneficial effects in diabetic 
neuropathy. The aim of this study was to investigate and compare the possible analgesic effects of melatonin 
and vitamin E in diabetic rats. 
Materials and Methods 
This study was performed on 32 male Wistar rats divided into 4 groups: control, diabetic, melatonin-treated 
diabetic and vitamin E-treated diabetic. Experimental diabetes was  induced  by intraperitoneal streptozotocin         
(50 mg/kg) injection. Melatonin (10 mg/kg, i.p.) and vitamin E (100 mg/kg, i.p.) were injected for 2 weeks after 
21st day of diabetes induction. At the end of administration period, pain-related behavior was assessed using  
0.5% formalin test according to two spontaneous flinching and licking responses. The levels of lipid peroxidation 
as well as glutathione-peroxidase and catalase activities were evaluated in lumbosacral dorsal root ganglia. 
Results 
Formalin-evoked flinching and total time of licking were increased in both acute and chronic phases of pain 
in diabetic rats as compared to control rats, whereas treatment with melatonin or vitamin E significantly 
reduced the pain indices. Furthermore, lipid peroxidation levels increased and glutathione-peroxidase and 
catalase activities decreased in diabetic rats. Both antioxidants reversed the biochemical parameters toward 
their control values. 
Conclusion 
These results suggest that oxidative stress may contribute to induction of pain in diabetes and further suggest 
that antioxidants, melatonin and vitamin E, can reduce peripheral neuropathic pain in streptozotocin-induced 
diabetic rats. 
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Introduction 
Diabetes mellitus comprises a group of chronic 
diseases  characterized  by  hyperglycemia       
(1, 2). The long-term hyperglycemia increases 
glycation proteins and lipids, enhances glucose 
auto-oxidation and changes the activity of 
many cellular enzymes (1-3). Wolff and Dean 
(3) were the first to show that glucose auto-
oxidation generates reactive oxygen species 
(ROS). These species lead to the chronic 
oxidative stress in diabetes mellitus (4). ROS 
also have toxic effects upon the structure and 
function of various organs, inducing 
retinopathy, nephropathy, vascular 
complications and neuropathy (1, 3, 4). 
Oxidative damage to the peripheral neurons 
often leads to an increased activity of spinal 
glial cells and nerve fibers, and to release of 
preinflammatory factors, cytokines and 
glutamate, as well as augmented sensitivity to 
painful stimuli (5). Abnormal sensations and 
pain are features of approximately 10% of all 
cases of diabetic neuropathy and can cause 
marked diminution in the quality of life for 
these patients (6). Like other neuropathic pain 
states, painful diabetic neuropathy has an 
unknown pathogenesis and, in many cases, is 
not alleviated by non-steroidal anti-
inflammatory drugs or opiates (6). Also these 
drugs may cause intolerable side effects. 
Therefore, investigation of other options of 
treatment such as antioxidants is needed. 
Melatonin (N-acetyl-5-methoxytriptamin) is 
an endogenous neurohormone produced by the 
pineal gland in mammals. Its synthesis is 
augmented in darkness and inhibited by the 
exposure of animals to light. This compound 
participates in a number of physiological 
processes, like the reproduction regulation and 
circadian rhythms (7, 8). At the same time, 
melatonin is an effective scavenger of different 
free radicals (9). It also crosses all morpho-
physiological barriers and enhances the 
expression of antioxidant enzymes in all cells 
(10). Vitamin E is a lipid soluble antioxidant 
which especially protects biological 
membranes from lipid peroxidation (11). It has 
been shown that melatonin and vitamin E 
reduce several diabetes-induced complications 
in animals such as oxidative-antioxidative 
status (4, 12). There is evidence about efficacy 
of antioxidants such as vitamin E on 
neuropathic pain (13). Possible participation of 
melatonin MT2 and δ opioid receptors in the 
antinociceptive activity of melatonin in 
diabetic rats has also been suggested (14). 
However, up to now, the antioxidative role of 
melatonin on peripheral neuropathic pain has 
not been elucidated in diabetes. Since 
melatonin demonstrates good antioxidative 
property, we have hypothesized that melatonin 
could reduce peripheral neuropathic pain by 
decreasing the oxidative stress in diabetic rats. 
Therefore, the purpose of this study was to 
assess the possible analgesic effect of 
melatonin due to its antioxidant activity in 
diabetic rats and to compare it with vitamin E. 
 
Materials and Methods 
Animals and treatment 
Thirty two male Wistar rats weighing 180-220 
g each were used in the study. The animal 
room temperature was maintained at 22±2 ˚C, 
under a 12 hr/ 12 hr light/dark cycle with 
lights on from 8:30 am. Food and water were 
available  ad libitum. All animals were 
randomly divided into two groups: control and 
diabetic. Animals were rendered diabetic by an 
intraperitoneal injection of 50 mg/kg 
streptozotocin only once. Streptozotocin was 
dissolved in 0.05 M citrate buffer at pH 4.5 
immediately before administration. Control 
rats (n=8) were injected with the vehicle alone. 
Blood glucose levels as a parameter of 
diabetes mellitus were determined using a 
glucometer (ACON Laboratories, Inc., USA) 
and a tail vein 72 hr later. The rats with 
hyperglycemia (glucose higher than 220 
mg/dl) were considered as diabetic. Maturing 
animals exposed to chronic hyperglycemia 
manifest pathological alterations in peripheral 
nerve structure and function, and are relevant 
models for studying the diabetic peripheral 
neuropathy (15). Accordingly three weeks 
after streptozotocin injection, glycemia was 
again determined and all rats with a final blood 
glucose levels above 220 mg/dl were randomly 
assigned to three groups (each were included 
eight rats): the first group received daily 
melatonin at a dose of 10 mg/kg  
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intraperitoneally. Melatonin was dissolved in 
ethanol and this solution was then diluted with 
saline to a final volume (final concentration of 
ethanol, 4%). The second group received daily 
vitamin E dissolved in corn oil containing 4% 
ethanol at a dose of 100 mg/kg 
intraperitoneally. The third group of diabetic 
rats and the control group were injected with 
vehicle alone (16). Study design contains the 
control groups and the melatonin and vitamin 
E doses used in this study were chosen on the 
basis of previously published experiments   
(16, 17). All solutions were intraperitoneally 
injected at a volume of 0.1 ml per 100 g body 
weight for 2 weeks. All chemicals were 
purchased from Sigma (St. Louis, MO, USA). 
The study was performed following the ethical 
guidelines of the International Association for 
the Study of Pain, and the experimental 
protocol was reviewed and approved by the 
Local Institutional Committee for the Ethical 
Use of Animals. 
 
Formalin test 
At the end of administration period, pain-
related biphasic responses were measured by 
formalin test. This occurred 24 hr after the last 
melatonin or vitamin E injection for 
investigation of the efficacy of long-term 
treatment. All animals were acclimated to the 
experimental setting, by placement in an open 
plexiglas observation chamber for 30 min 
before formalin injection. Plexiglas chamber 
was placed on the surface of glass and beneath 
it, was mounted a large mirror at a 45˚ angle to 
allow an unobstructed view of the animal 
paws. Fifty microliters of 0.5% formalin 
(prepared by diluting a commercial solution in 
sterile 0.9% NaCl) were injected 
subcutaneously (s.c.) into the dorsal surface of 
the right hind paw (18) using a syringe 
equipped with a 30 gauge needle. After the 
injection, rats were immediately put back into 
the  plexiglas  chamber,  and  observed  for         
60 min. Only one animal was tested at one 
time. The formalin-induced pain-related 
responses were assessed in all rats by the same 
investigator, by quantifying two behaviors: 
licking the injected paw and flinching. Each 
episode of shaking or vibrating the injected 
paw or shudder of the back/hind quarters was 
recorded as one flinch, as previously described 
(19). The number of the flinches was 
quantified during 1-min periods every 5 min, 
up to 60 min after injection (19). The amount 
of time (expressed in sec), animals spent in 
licking the injected paw, was recorded up to    
1 hr (20). For each behavioral parameter, 
cumulative values were calculated for each of 
the tow phases of the response to formalin, in 
agreement with previous studies (14, 18). Data 
collected between 0 and 10 min post-formalin 
injection correspond to phase 1 (acute pain) 
and between 15 and 60 min post-formalin 
injection correspond to phase 2 (chronic pain). 
Animals were used only once and at the end of 
the formalin test each rat was anesthetized by 
ketamine/xylazine and after a skin incision, the 
left and right lumbosacral dorsal root ganglia 
were microdissected and immediately frozen 
at -20 ˚C until analysis. 
 
Biochemical measurements 
The lumbosacral dorsal root ganglia were 
homogenized in 1:10 (W/V) cold 25 mM 
potassium phosphate buffer (pH 7.4) and used 
to determine lipid peroxidation, glutathione 
peroxidase and catalase activities. 
Malondialdehyde (MDA) levels were 
estimated by the method of Esterbauer and 
Cheeseman (21). The degree of lipid 
peroxidation was assessed according to MDA 
formation, which is accepted as an index of 
lipid peroxidation. Malondialdehyde, an end-
product of fatty acid peroxidation, reacts with 
thiobarbituric acid (TBA) to form a colored 
complex. The principle of the method is the 
spectrophotometric measurement of the color 
generated by the reaction of the TBA with 
MDA. For this purpose, 300 µl of 10% 
trichloroacetic acid were added to 150 µl of 
each sample and centrifuged at 1000×g for 10 
min at 4 ˚C. Three hundred microliters of the 
supernatant were transferred to a test tube and 
incubated with 300 µl 0.67% thiobarbituric 
acid at 100 ˚C for 25 min. The mixture was 
allowed to cool on water for 5 min. The 
resulting pink stained TBA-RS were 
determined in a spectrophotometer at 535 nm. 
TBA-RS were quantified using an extinction  
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coefficient of 1.56×10
5 M
-1 cm
-1 and expressed 
as nmol of MDA per g wet tissue. 
Glutathione peroxidase activity was 
measured according to the method of 
Lawrence and Burk (22). The enzymatic 
reaction was initiated in the tube that 
contained reduced nicotinamide adenine 
dinucleotide phosphate, reduced glutathione, 
sodium azide and glutathione reductase by the 
addition of cumene hydroperoxide (CuOOH) 
and the change in absorbance at 340 nm was 
monitored with a spectrophotometer. Activity 
is given in unit per mg protein. 
Catalase activity was assayed measuring the 
absorbance decrease at 240 nm in a reaction 
medium containing 30 mM H2O2, 50 mM 
potassium phosphate buffer pH 7.0 and 50 µl 
of the sample, according to Aebi method (23). 
One unit of enzyme is defined as one µmol of 
H2O2 consumed per min and the specific 
activity is reported as unit per mg protein. 
Protein concentrations were determined 
according to the method of Lowry et al (24). 
 
Statistical analysis 
All data were expressed as mean±SEM for 8 
animals per group. For the formalin test, 
flinches/min curve was used for the mean 
number of flinches against time. The area 
under the number of flinches against time 
curve (AUC) for both phases was calculated 
according to trapezoidal rule. Statistical 
analyses were performed for each behavioral 
parameter and biochemical data by one-way 
analysis of variance (ANOVA) followed by 
Tukey’s test, using the software package SPSS 
for windows (SPSS, Inc., USA). 
 
Results 
Effects of diabetes and antioxidants 
treatment on the pain-related activities 
Behavioral responses in the experimental 
groups are reported in Figure 1 and 2. All rats 
exposed to 0.5% formalin exhibited the 
biphasic pattern of this test characterized by 
two periods of behavioral responses of the 
injected hind paw, separated by a period of 
decreased activity. 
Flinching behavior was affected by 
streptozotocin administration (Figure 1A). The 
overall analyses of flinching behavior as AUC, 
showed a significant difference (P< 0.05) 
between the diabetic and control rats during 
the second phase (Figure 1C). Whereas 
additional analyses of AUC revealed that there 
was no significant difference between the 
control and diabetic groups during the first 
phase (Figure 1B). 
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Figure 1. Formalin-evoked flinching behavior. A) Time 
course of the pain-related activities induced by 0.5% 
formalin. B) and C) The area under the number of 
flinches against time curve (AUC) as formalin induced 
pain-related activities during 1st and 2nd phases, 
respectively. Data are expressed as mean±SEM for 8 
animals per group. *P< 0.05 in comparison with control 
values, 
#P< 0.05 in comparison with diabetic values.  
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The licking behavior was also increased in 
diabetic rats as compared to control rats 
(Figure 2). The time spent in licking the 
injected paw was significantly (P< 0.05)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Time spent in licking during in A) 1st and B) 
2nd phases of formalin test. Data are expressed as 
mean±SEM for 8 animals per group. *P< 0.05 in 
comparison with control values, 
#P< 0.05 in comparison 
with diabetic values. 
 
higher in diabetic rats compared to the control 
rats, in both first (Figure 2A) and second 
(Figure 2B) phases of the behavioral response. 
Intraperitoneal administration of melatonin 
or vitamin E significantly (P< 0.05) reduced 
pain-induced  flinches  in  diabetic  rats         
(Figure 1A). AUC analyses revealed that 
treatment with melatonin or vitamin E 
significantly (P< 0.05) decreased flinching 
behavior during phase 2 (Figure 1C) in 
diabetic rats but not in phase 1 (Figure 1B). 
The licking behavior was also significantly 
affected by melatonin and vitamin E 
administration (Figure 2). Treatment with 
melatonin or vitamin E significantly (P< 0.05) 
reduced the amount of total time spent licking 
the injected paw in diabetic rats in second 
phase (Figure 2A) but not in the first phase 
(Figure 2B) of pain. 
 
Effects of diabetes and antioxidants 
treatment on biochemical parameters in 
dorsal root ganglia 
In the present study we determined the levels 
of lipid peroxidation, and glutathione 
peroxidase and catalase activities in 
lumbosacral dorsal root ganglia. The lipid 
peroxidation levels in dorsal root ganglia from 
diabetic rats was significantly (P< 0.05) 
increased, whereas the glutathione peroxidase 
and catalase activities significantly (P< 0.05) 
decreased. Treatment with melatonin or 
vitamin E returned the levels of lipid 
peroxidation and glutathione peroxidase and 
catalase activities toward their control values 
(Table 1). 
 
 
 
Table 1. The effects of melatonin and vitamin E on the activity of antioxidative enzymes and malondialdehyde levels in 
dorsal root ganglia (mean±SEM)  
Vitamin E  Melatonin  Diabetic  Control    
 
24.24±2.23 
b 
 
23.45±2.25 
b 
 
36.75±1.74
 a 
 
20.04±2.02  Malondialdehyde 
nmol/g wet tissue 
 
0.031±0.001
 b 
 
0.035±0.003 
b 
 
0.023±0.002
 a 
 
0.032±0.002  Glutathione peroxidase 
U/mg protein 
 
0.131±0.003 
b 
 
0.131±0.001 
b 
 
0.098±0.007 
a 
 
0.146±0.015 
Catalase  
U/mg protein 
a P<0.05 vs control group. 
b P<0.05 vs diabetic group.  
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Discussion 
Streptozotocin-induced diabetes is 
accompanied by chronic oxidative stress due 
to the resulting hyperglycemia (25). Enhanced 
generation of reactive oxygen species occurred 
during the hyperglycemia contributes to the 
increased neuronal damage by oxidizing 
proteins, lipids, and augmented levels of lipid 
peroxidation products in cellular membranes 
(26, 27). Oxidative partial damage to the 
peripheral neurons often leads to an 
augmented sensitivity to painful stimuli and 
peripheral neuropathic pain (5). Maturing 
animals exposed to chronic hyperglycemia 
manifest pathological alterations in peripheral 
nerve structure and function, and are relevant 
models for studying the diabetic peripheral 
neuropathy (15). Different studies indicate that 
various ROS scavengers reduce pain behaviors 
predominantly through peripheral nerve 
protection (28, 29). In the current study we 
have examined the effects of treatment with 
melatonin or vitamin E on the peripheral 
neuropathic pain in diabetic rats. The 
treatment was aimed at reducing the oxidative 
stress and suppressing the hyperactivity of the 
abnormal nerves; and we investigated the 
levels of lipid peroxidation and the antioxidant 
enzymes activities in dorsal root ganglia. 
These tissues are the relevant structures for 
investigation of peripheral neuropathy (30). 
In the present study, administration of 
streptozotocin significantly increased 
malondialdehyde levels in the dorsal root 
ganglia studied. One reason for the elevated 
lipid peroxidation in streptozotocin-induced 
diabetes is the reduction of antioxidant 
enzymes such as glutathione peroxidase and 
catalase activities. In this experiment we found 
that untreated diabetes caused reduced 
activities of glutathione peroxidase and 
catalase in dorsal root ganglia. Our findings 
are consistent with the previously published 
reports (31, 32). It has been shown that the 
antioxidant enzymes activities were changed 
in peripheral nerve tissues in chronic 
experimental diabetic neuropathy. These 
changes have been related to duration of 
diabetes or post-translational modifications 
(31). 
In our study, treatment of diabetic animals 
with either melatonin or vitamin E 
significantly reduced lipid peroxidation in the 
dorsal root ganglia. Furthermore, we found 
that a decrease of glutathione peroxidase and 
catalase activities in peripheral nerve 
structures was reversed by the administration 
of melatonin or vitamin E. Despite 
considerable evidence identifying melatonin 
and vitamin E as potent antioxidants (12, 17, 
33), their protective effects against oxidative 
stress in dorsal root ganglia have not been 
reported to date. This is the first report to show 
that melatonin and vitamin E protect these 
structures against oxidative stress. 
Nevertheless, beneficial effects of several 
antioxidants such as α-lipoic acid and dietary 
antioxidant supplements on structure and 
function of peripheral neurons have been 
reported previously (25, 28, 29, 34).  It is 
important to mention that peripheral nerve 
antioxidant defenses are very low compared to 
central nerves (32). 
In the current study we have further 
examined the effects of antioxidants, 
melatonin or vitamin E on suppression of pain-
related activities in diabetic rats by the 
formalin test. We showed that diabetes could 
significantly lead to the hypersensitivity to 
formalin injection. Previously increase in 
peripheral nociception, as revealed by the 
formalin response, has been demonstrated in 
streptozotocin induced diabetes (14, 18). 
Increase in peripheral neuropathic pain in 
diabetic rats could be due to a peripheral 
release of cholecystokinin, which in turn 
would act on receptors located on the primary 
afferent neurons (18). However, oxidative 
stress also contributes to the peripheral 
neuropathic pain during hyperglycemia (5, 
29). Therefore, antioxidants might be of 
general use in the prevention of nerve damage 
and peripheral neuropathic pain associated 
with diabetes (13, 29). Herein we found that 
melatonin and vitamin E could reduce the 
pain-related activities during the formalin test. 
Vissers et al (35) have shown the correlation 
between the formalin test and the neuropathic 
pain behavior in different species of 
experimental models. Therefore, it has been  
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speculated that melatonin and vitamin E have 
reduced the peripheral neuropathic pain in 
diabetic rats. Sayyed et al (36) have shown 
that treatment with U83836E prevented the 
hyperalgesia in diabetic rats; in this study 
U83836E acted as an antioxidant to reduce 
oxidative damage to the peripheral neurons 
and ameliorated the alterations in lipid 
peroxidation products levels and antioxidant 
enzymes in diabetic rats. 
The exact mechanism of analgesic effects 
of melatonin in diabetes is still under debate. 
Arreola-Espino et al (14) have suggested the 
possible participation of melatonin MT2 and δ 
opioid receptors in the antinociceptive activity 
of melatonin in diabetic rats. Based on our 
findings, melatonin and vitamin E can reverse 
the reduced activities of antioxidant enzymes 
and increased lipid peroxidation in peripheral 
nerve system, and thereby can improve 
neuropathic pain in diabetes mellitus. 
Therefore both oxidative stress and peripheral 
neuropathic pain were concomitantly 
prevented by the treatment with melatonin or 
vitamin E suggesting that oxidative stress was 
probably involved in the diabetes-induced 
peripheral neuropathic pain. Especially the 
analgesic effects of melatonin and vitamin E 
prominently appeared in chronic phase of pain 
indicating that ROS are critically involved in 
the maintenance of persistent neuropathic pain. 
Herein we also compared the effects of 
melatonin and vitamin E on the pain-related 
activities. There was no significant difference 
between these two antioxidants on peripheral 
neuropathic pain, however the vitamin E dose 
used in the present study was ten times higher 
than the melatonin dose. Therefore, it is 
possible to postulate that melatonin is a more 
potent antioxidant than vitamin E to prevent 
development of diabetic complications. 
 
Conclusion 
In summary, this study showed the 
involvement of oxidative stress in peripheral 
neuropathic pain in diabetes mellitus by 
damaging the peripheral neurons; whereas the 
antioxidants, melatonin and vitamin E, show 
analgesic activities in diabetic rats by 
preventing the nerve oxidative damage. Our 
data suggest that either melatonin or vitamin E 
may be useful in the prevention of pain 
associated with diabetes. However vitamin E 
was found to be less effective than melatonin 
in alleviation of pain. 
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